Deuterated 2-amino-3-hydroxypropanoic acid derivatives
This invention relates to novel 2-amino-3-hydroxypropanoic acid derivatives and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an NMDA glycine-site antagonist.
1. A compound of formula I:
or a pharmaceutically acceptable salt thereof, wherein:
Y 1 is CD 3 ;
Y 2 is CD 3 ;
each Z variable is independently selected from hydrogen and deuterium; and
each R variable is independently selected from hydrogen and deuterium.
2. The compound of claim 1 wherein each Z variable is hydrogen.
3. The compound of claim 1 wherein each Z is deuterium.
4. The compound of claim 1 which is selected from the group consisting of the following:
or a pharmaceutically acceptable salt of any of the foregoing.
5. The compound of claim 4 , wherein the compound is an (R) enantiomer, or a pharmaceutically acceptable salt thereof, which is substantially free of the corresponding (S) enantiomer.
6. The compound of claim 4 , wherein the compound is an (S) enantiomer, or a pharmaceutically acceptable salt thereof, which is substantially free of the corresponding (R) enantiomer.
7. A compound of the following formula:
or a pharmaceutically acceptable salt thereof.
8. The compound of claim 1 , wherein any atom not designated as deuterium is present at its natural isotopic abundance.
9. A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
10. The composition of claim 9 for use in treating a disease or disorder associated with aberrant NMDA receptor function.
11. The composition of claim 9 for use in treating epilepsy, diabetic neuropathic pain, fibromyalgia, osteoarthritis, or migraine.
12. The compound of claim 4 , wherein the compound has the formula:
or a pharmaceutically acceptable salt thereof.
13. The compound of claim 12 , wherein the compound is an (R) enantiomer, or a pharmaceutically acceptable salt thereof, which is substantially free of the corresponding (S) enantiomer.
14. The compound of claim 13 , wherein any atom not designated as deuterium is present at its natural isotopic abundance.
15. A composition comprising a compound of claim 14 and a pharmaceutically acceptable carrier.
16. The composition of claim 15 for use in treating a disease or disorder associated with aberrant NMDA receptor function.
17. The composition of claim 15 for use in treating epilepsy, diabetic neuropathic pain, fibromyalgia, osteoarthritis, or migraine.